Moffitt Plays Pivotal Role in FDA Approval of Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma

The first-of-its-kind cellular immunotherapy uses the patient’s immune cells to seek out and kill their cancer

Moffitt Study Finds Neoadjuvant Chemotherapy Significantly Improves Outcomes for Penile Squamous Cell Carcinoma Patients

The largest retrospective cohort analysis to date provides much-needed evidence to help guide therapeutic decisions

Moffitt Develops First Individualized Predictive Model for Multiple Myeloma Treatment

Genomics are used to expand biological classification and improve prognostic decisions

Moffitt Study Suggests Improvements Needed for Patient-Reported Outcome Data in Genitourinary Cancer Clinical Studies

Systematic review shows delays in reporting and lower quality analyses

Dr. Karen Lu Joins Moffitt Cancer Center as New Executive Vice President, Physician in Chief

She will oversee the Moffitt Medical Group

New Reagent Improves the Process of Making Sulfur-Containing Compounds that May Be Used in Medicines

t-BuSF reagent improves efficiency of sulfoximine, sulfonimidoyl fluoride and sulfonimidamide synthesis

Researchers Identify Key Characteristics Associated with Improved CAR T Outcomes in Large B Cell Lymphoma

Analysis of ZUMA-7 trial patients showed B-cell gene expression signature and high CD19 protein expression correlated with improved axicabtagene...

Deregulation of Alternative RNA Splicing Promotes Pancreatic Cancer Progression and Metastasis

Loss of RBFOX2 protein promotes pancreatic cancer metastasis through effects on cytoskeletal remodeling

Moffitt Researchers Characterize the Tumor Suppressor Activity of the PTEN Protein in Melanoma

PTEN suppresses disease development through its lipid phosphatase activity and inhibition of the AKT/mTOR/FRA1 pathway

News Releases